Predictive In Vitro Models
Developing Better Models to Predict Clinical Outcomes
21 – 22 September 2011
Double Tree Suites Hilton, Boston, MA, USA
Laszlo UrbanGlobal Head, Preclinical Safety Profiling Novartis
Donna DambachDirector, Investigative Toxicology Genentech
Andre LevchenkoAssociate Professor The John Hopkins University
John DavisDirector of Investigative Toxicology, Drug Safety R&D Pfizer
With high rates of efficacy and safety failures in the clinic, drug developers need to ensure that improved prediction of clinical effect is achieved earlier in the drug development pipeline.
But how do you achieve validation of a new in vitro assay or model? How have different tools performed so far and what new technologies are being developed? What are the challenges and opportunities of integrating stem cells into the pre-clinical space for safety and efficacy screening and investigation?
The 2nd Annual Predictive In Vitro Models summit brings together the world’s experts in Boston this year to tackle these challenges. In putting together this meeting we have spoken to leading drug developers and academia, to identify the most critical issues currently facing the industry and turned this into an essential program.
Register Now | Download Brochure | Prices & Discounts
Last year's delegates left the event having gained excellent insight into new technology and methodologies. Alongside the content, the event benefited from participation from a diverse and engaged audience. The event was such a success that an amazing 95% of the delegates said that they would recommend the event to a colleague.
Building on last year's success, Predictive In Vitro Models 2011 will again, provide a focussed forum for pharma, biotechs and academia to share best practice and find solutions for developing better models to predict drug efficacy and toxicity.
Here's just one piece of feedback from last year's event:
“Excellent state-of-the-art for in vitro technology and practical pharma examples. An extremely good snapshot of where the field is"
Katya Tsaioun, CSO, Cyprotex
“An excellent opportunity to find out what other pharma are doing and what’s emerging. Very valuable.” AstraZeneca
“Good exchange. Interesting topics and a great mix of industry and academia. Collegial exchange of ideas is always valuable” Genentech
